Retrospective review of MET gene mutations

Maryam Zenali, James DeKay, Zesheng Liu, Stanley Hamilton, Zhuang Zuo, Xinyan Lu, Rania Bakkar, Gordon Mills, Russell Broaddus

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


C-MET proto-oncogene is a tyrosine kinase situated on chromosome 7. C-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) play a role in proliferation, differentiation and organ development. C-MET genetic aberrations are found associated with driving tumorigenesis. In this retrospective study, we reviewed molecular analysis data gathered from a cancer institute during a two-year period (2010-2012). Upon detection of tumors harboring c-MET mutations, we determined the status of the other mutations tested and evaluated c-MET expression by fluorescent in-situ hybridization (FISH). Our search resulted in identification of 134 c-MET mutations, 44% of which had mutations of at least one of the other genes tested. No c-MET expression aberrancy was detected in this subset by FISH. Survival amongst the patients with surgically resected metastatic colorectal cancers (CRC) was slightly better in those with only a c-MET mutation compared to those with no mutation detected, although the difference was not statistically significant. When c-MET inhibition becomes an integrated part of chemotherapy practice, our observed frequency of co-mutations will be an argument for utilizing c-MET targeted treatment in combination with other targeted drugs and therapeutic strategies. Larger studies can aid to further parse out c-MET prognostic and therapeutic significance.

Original languageEnglish (US)
Pages (from-to)533-541
Number of pages9
Issue number5
StatePublished - 2015
Externally publishedYes


  • C-MET
  • Co-mutations
  • FISH
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Retrospective review of MET gene mutations'. Together they form a unique fingerprint.

Cite this